MONALEESA-7 is a phase III randomized, double-blind, placebo-controlled study of ribociclib or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+/HER2− advanced BC [40]. The gene discussed is HR; the disease is breast cancer.